VYNE Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From VYNE Therapeutics Inc.
Keeping Track: Pediatric Approvals, Seres Starts C Diff Submission, And BMS Pulls Reblozyl sBLA Before Possible CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
In immuno-oncology and beyond, Chinese investors are setting their sights on new targets in the biopharma arena.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
- Topical Delivery
- Drug Delivery
- Other Names / Subsidiaries
- Foamix Pharmaceuticals Ltd.
- Tigercat Pharma, Inc.
- Menlo Therapeutics, Inc.